| |
著者: Nobuyuki Horita, Masaki Yamamoto, Takashi Sato, Toshinori Tsukahara, Hideyuki Nagakura, Ken Tashiro, Yuji Shibata, Hiroki Watanabe, Kenjiro Nagai, Kentaro Nakashima, Ryota Ushio, Misako Ikeda, Nobuaki Kobayashi, Masaharu Shinkai, Makoto Kudo, Takeshi Kaneko
雑誌名: Sci Rep. 2016 Jan 11;6:18999. doi: 10.1038/srep18999. Epub 2016 Jan 11.
Abstract/Text
Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for efficacy and safety by the AMR single agent regimen as second-line chemotherapy for a patient with SCLC. Binary data were meta-analyzed with the random-model generic inverse variance method. We included nine articles consisted of 803 patients. The pooled three-, six-, and nine-month progression-free survival were 63% (95% CI 57-69%, I(2) = 53%), 28% (95% CI 21-35%, I(2) = 71%), and 10% (95% CI 6-14%, I(2) = 41%), respectively. The pooled six-, 12-, and 18-month overall survival were 69% (95% CI 61-78%, I(2) = 83%), 36% (95% CI 28-44%, I(2) = 80%), and 15% (95% CI 8-21%, I(2) = 81%), respectively. Amrubicin seemed much more beneficial for Japanese patients. However, compared to the efficacy of topotecan presented in a previous meta-analysis, amrubicin may be a better treatment option than topotecan for both Japanese and Euro-American. Adverse effects by amrubicin were almost exclusively observed to be hematological. Notably, grade III/IV neutropenia incidence was 70% and febrile neutropenia incidence was 12%.
PMID 26750506 Sci Rep. 2016 Jan 11;6:18999. doi: 10.1038/srep18999. Epub 2016 Jan 11.
|
